Related Experiment Video
Updated: Apr 14, 2026
Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Comparative prognostic value of inflammation-based biomarkers for predicting in-hospital mortality in severe acute
Wenzhen Zhou1, Hanwen Tong2, Lingli Wu1
1Department of Emergency Medicine, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Background:
Inflammation is central to the progression of severe acute pancreatitis (SAP), but the comparative prognostic value of inflammation-based biomarkers remains unclear. This study evaluated six indices-the systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), glucose-to-lymphocyte ratio (GLR), and lactate-to-albumin ratio (LAR)-for predicting in-hospital mortality in SAP.
Methods:
This retrospective study included 435 SAP patients admitted to a tertiary intensive care unit, from 2015 to 2024. Biomarkers were measured within 24 hour of admission. Logistic regression was used to identify independent predictors. Discriminatory performance was assessed with receiver operating characteristic (ROC) curves. Non-linear associations were examined using restricted cubic splines, and sensitivity analyses were performed using Youden index-based cutoffs.
Results:
A total of 101 patients (23.2%) died during hospitalization. NLR, GLR, and LAR were independently associated with mortality, with LAR showing the strongest effect (adjusted odds ratio = 1.48). LAR demonstrated good discrimination (area under the curve [AUC] =0.710), comparable to the sequential organ failure assessment (SOFA) score (AUC = 0.741; P = 0.249). Adding LAR to SOFA resulted in a small but statistically significant improvement in discrimination (AUC = 0.753 vs. 0.741; P = 0.036), although the clinical impact of this incremental gain remains uncertain. Restricted cubic spline analyses showed approximately linear associations for all three biomarkers, and sensitivity analyses confirmed the robustness of these findings.
Conclusion:
LAR was the most informative inflammation-based biomarker for early mortality prediction in SAP, with performance comparable to the SOFA score. Its simplicity and predictive ability suggest that LAR may serve as a useful adjunct to existing scoring systems for early risk assessment.
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: